Alyeska Investment Group L.P. Takes $4.70 Million Position in Humacyte, Inc. $HUMA

Key Points

• Alyeska Investment Group acquired 6.02 million Humacyte shares worth approximately $4.7 million, representing about 2.23% of the company. Institutional investors collectively own 44.71% of HUMA.
• Humacyte shares fell 5.2% and opened at $0.57, near the stock’s 52-week low. The company reported a quarterly loss of $0.16 per share and revenue of $0.41 million, missing analyst expectations for both measures.
• Analyst sentiment remains mixed, with six Buy ratings and one Sell rating; the consensus rating is “Moderate Buy,” with a target price of $6.54. Humacyte is developing regenerative human acellular vessels for vascular access and repair applications.

Alyeska Investment Group L.P. purchased a new position in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 6,022,925 shares of the company's stock, valued at approximately $4,700,000. Alyeska Investment Group L.P. owned about 2.23% of Humacyte at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. UBS Group AG grew its stake in Humacyte by 48.8% in the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company's stock valued at $2,862,000 after purchasing an additional 976,275 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Humacyte in the 2nd quarter worth about $785,000. Ieq Capital LLC purchased a new stake in shares of Humacyte during the 2nd quarter worth about $218,000. Stonepine Capital Management LLC purchased a new stake in shares of Humacyte during the 2nd quarter worth about $180,506. Finally, LaSalle St. Investment Advisors LLC purchased a new stake in shares of Humacyte during the 2nd quarter worth about $89,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Stock Down 5.2%

Humacyte stock opened at $0.57 on Wednesday. The company has a debt-to-equity ratio of 2.07, a current ratio of 6.21 and a quick ratio of 5.74. Humacyte, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.55. The firm has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $0.87. The firm has a market cap of $158.46 million, a price-to-earnings ratio of -1.16 and a beta of 2.45.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.05). Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%.The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $1.04 million. As a group, analysts forecast that Humacyte, Inc. will post -0.4 earnings per share for the current year.

Wall Street Analyst Weigh In

HUMA has been the subject of several recent research reports. Wall Street Zen cut Humacyte from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. TD Cowen cut their price objective on shares of Humacyte from $1.50 to $1.25 and set a "buy" rating on the stock in a research report on Wednesday, June 17th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Humacyte in a research note on Wednesday, July 8th. Benchmark decreased their target price on shares of Humacyte from $2.00 to $1.00 and set a "speculative buy" rating for the company in a research report on Thursday, August 13th. Finally, HC Wainwright lifted their price objective on shares of Humacyte from $3.00 to $4.00 and gave the company a "buy" rating in a research note on Thursday, June 11th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $6.54.

Humacyte Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

Want to see what other hedge funds are holding HUMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humacyte, Inc. (NASDAQ:HUMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source